编辑精选——当代腹主动脉瘤生长率的系统综述与荟萃分析
该系统综述与荟萃分析纳入43项研究共28277例患者,评估2015年以来发表的小腹主动脉瘤生长率。平均生长率为2.38毫米/年(95%CI 2.16-2.60),随机对照试验估计为1.88毫米/年,临床观察性研究为2.31毫米/年,转化与放射学研究为2.85毫米/年。作者认为RESCAN关于小腹主动脉瘤监测的建议仍有效,但随机对照试验和高质量研究数据提示可能更低的生长率1.88-2.09毫米/年,需高质量前瞻性登记研究验证。
要点
- 平均腹主动脉瘤生长率为2.38毫米/年(95%CI 2.16-2.60),证据等级为低。
- 随机对照试验估计生长率为1.88毫米/年(95%CI 1.69-2.06),证据等级为高。
- 基线直径每增加1毫米,生长率增加0.08毫米/年(95%CI 0.024-0.137;p=0.005)。
核心结论
- 本研究估计当代腹主动脉瘤生长率为2.38毫米/年,未能证明随着腹主动脉瘤流行病学变化而出现任何有临床意义的生长率降低。
- 作者认为RESCAN关于小腹主动脉瘤监测的建议仍然有效。
- 随机对照试验和高质量研究数据的亚组分析结果提示可能更低的腹主动脉瘤生长率为1.88-2.09毫米/年,这些发现应在高质量前瞻性登记研究中验证。
研究设计与样本
- 系统综述遵循PRISMA指南,于2021年10月在MEDLINE、CENTRAL、PsycINFO、Web of Science核心合集和OpenGrey数据库中检索2015年以来发表的报告腹主动脉瘤生长率的研究。
- 共纳入43项研究、28277例患者:1241例来自随机对照试验,23941例来自临床观察性研究,3095例来自放射学或转化研究。
- 采用随机效应模型荟萃分析合并数据,通过I²统计量评估异质性,并对研究结果进行GRADE评估,方案注册于PROSPERO(CRD42022297404)。
主要发现
- 平均腹主动脉瘤生长率为2.38毫米/年(95%CI 2.16-2.60毫米/年;GRADE=低)。
- 经基线直径调整的荟萃回归分析显示,基线直径每增加1毫米,生长率增加0.08毫米/年(95%CI 0.024-0.137毫米/年;p=0.005)。
- 按研究类型分析,随机对照试验估计的生长率为1.88毫米/年(95%CI 1.69-2.06毫米/年;GRADE=高),临床观察性研究为2.31毫米/年(95%CI 1.95-2.67毫米/年;GRADE=中),转化与放射学研究为2.85毫米/年(95%CI 2.44-3.26毫米/年;GRADE=低)(p<0.001)。
- 低偏倚风险研究估计的生长率为2.09毫米/年(95%CI 1.87-2.32;GRADE=高)。
临床怎么用
- 作者认为RESCAN关于小腹主动脉瘤监测的建议仍然有效。
- 作者建议随机对照试验和高质量研究数据提示的潜在更低生长率1.88-2.09毫米/年应在高质量前瞻性登记研究中验证。
局限性
- 异质性高。
- 存在小研究发表偏倚(p=0.003)。
- 27项研究呈现中至高度偏倚风险。
- 随机对照试验和高质量研究数据提示的潜在更低生长率应在高质量前瞻性登记研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the contemporary growth rate of small abdominal aortic aneurysms (AAAs) in view of recent epidemiological changes, such as decreasing smoking rates and establishment of population screening programmes. DATA SOURCES: MEDLINE, CENTRAL, PsycINFO, Web of Science Core Collection, and OpenGrey databases. REVIEW METHODS: Systematic review following the PRISMA guidelines. In October 2021, databases were queried for studies reporting on AAA growth rates published from 2015 onwards. The primary outcome was contemporary AAA growth rates in mm/year. Data were pooled in a random effects model meta-analysis, and heterogeneity was assessed through the I2 statistic. GRADE assessment of the findings was performed. The protocol was published in PROSPERO (CRD42022297404). RESULTS: Of 8 717 titles identified, 43 studies and 28 277 patients were included: 1 241 patients from randomised controlled trials (RCTs), 23 941 from clinical observational studies, and 3 095 from radiological or translational research studies. The mean AAA growth rate was 2.38 mm/year (95% CI 2.16 - 2.60 mm/year; GRADE = low), with meta-regression analysis adjusted for baseline diameter showing an increase of 0.08 mm/year (95% CI 0.024 - 0.137 mm/year; p = .005) for each millimetre of increased baseline diameter. When analysed by study type, the growth rate estimated from RCTs was 1.88 mm/year (95% CI 1.69 - 2.06 mm/year; GRADE = high), while it was 2.31 mm/year (95% CI 1.95 - 2.67 mm/year; GRADE = moderate) from clinical observational studies, and 2.85 mm/year (95% CI 2.44 - 3.26 mm/year; GRADE = low) from translational and radiology based studies (p < .001). Heterogeneity was high, and small study publication bias was present (p = .003), with 27 studies presenting a moderate to high risk of bias. The estimated growth rate from low risk studies was 2.09 mm/year (95% CI 1.87 - 2.32; GRADE = high). CONCLUSION: This study estimated a contemporaneous AAA growth rate of 2.38 mm/year, being unable to demonstrate any clinically meaningful AAA growth rate reduction concomitant with changed AAA epidemiology. This suggests that the RESCAN recommendations on small AAA surveillance are still valid. However, sub-analysis results from RCTs and high quality study data indicate potential lower AAA growth rates of 1.88 - 2.09 mm/year, findings that should be validated in a high quality prospective registry.
引用
- Prendes CF, Gouveia E Melo R, Caldeira D, et al. Editor's Choice - Systematic Review and Meta-Analysis of Contemporary Abdominal Aortic Aneurysm Growth Rates. Eur J Vasc Endovasc Surg. 2023. PMID: 37777049. doi:10.1016/j.ejvs.2023.09.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。